New method of targeting mutant RAS provides hope for cancer

As a 10-year journey comes to fruition, MUSC Hollings Cancer Center researcher John O’Bryan, Ph.D., and colleagues have demonstrated a new therapeutic

Related Keywords

United States , American , John Obryan , Shohei Koide , Hollings Cancer Center , University Of South Carolina , Department Of Veterans Affairs , Perlmutter Cancer Center At New York University , American Cancer Society , Department Of Cell , Cancer Center , Johno Bryan , Molecular Pharmacology , Experimental Therapeutics , Medical University , South Carolina , Perlmutter Cancer Center , New York University , Veterans Affairs ,